News Image

NASDAQ:SWAV qualifies as a high growth stock and is consolidating.

By Mill Chart

Last update: Mar 13, 2024

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if SHOCKWAVE MEDICAL INC (NASDAQ:SWAV) is suited for growth investing, while it is forming a base and may be ready to breakout. Investors should of course do their own research, but we spotted SHOCKWAVE MEDICAL INC showing up in our growth with base formation screen, so it may be worth spending some more time on it.

Assessing Growth Metrics for NASDAQ:SWAV

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:SWAV has received a 8 out of 10:

  • SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.08%, which is quite impressive.
  • SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.16%.
  • Measured over the past years, SWAV shows a very strong growth in Revenue. The Revenue has been growing by 126.31% on average per year.
  • SWAV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.88% yearly.
  • The Revenue is expected to grow by 20.28% on average over the next years. This is a very strong growth

How We Gauge Health for NASDAQ:SWAV

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:SWAV was assigned a score of 6 for health:

  • SWAV has an Altman-Z score of 8.29. This indicates that SWAV is financially healthy and has little risk of bankruptcy at the moment.
  • SWAV has a better Altman-Z score (8.29) than 87.24% of its industry peers.
  • With an excellent Debt to FCF ratio value of 4.42, SWAV belongs to the best of the industry, outperforming 84.69% of the companies in the same industry.
  • A Current Ratio of 11.76 indicates that SWAV has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 11.76, SWAV belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
  • SWAV has a Quick Ratio of 10.73. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
  • SWAV has a Quick ratio of 10.73. This is amongst the best in the industry. SWAV outperforms 92.86% of its industry peers.

Profitability Examination for NASDAQ:SWAV

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SWAV has achieved a 6:

  • The Return On Assets of SWAV (9.40%) is better than 91.84% of its industry peers.
  • SWAV's Return On Equity of 22.03% is amongst the best of the industry. SWAV outperforms 95.92% of its industry peers.
  • SWAV's Return On Invested Capital of 9.19% is amongst the best of the industry. SWAV outperforms 88.78% of its industry peers.
  • Looking at the Profit Margin, with a value of 20.17%, SWAV belongs to the top of the industry, outperforming 95.41% of the companies in the same industry.
  • The Operating Margin of SWAV (21.78%) is better than 94.90% of its industry peers.
  • The Gross Margin of SWAV (86.93%) is better than 96.94% of its industry peers.
  • SWAV's Gross Margin has improved in the last couple of years.

Why is NASDAQ:SWAV a setup?

Besides the Technical Rating, ChartMill also assign a Setup Rating to every stock. This setup score also ranges from 0 to 10 and determines to which extend the stock is consolidating. This is achieved by evaluating multiple short term technical indicators. NASDAQ:SWAV currently has a 8 as setup rating:

SWAV has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately. There is very little resistance above the current price. There is a support zone below the current price at 258.42, a Stop Loss order could be placed below this zone. Another positive sign is the recent Pocket Pivot signal.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

Our latest full fundamental report of SWAV contains the most current fundamental analsysis.

Our latest full technical report of SWAV contains the most current technical analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

SHOCKWAVE MEDICAL INC

NASDAQ:SWAV (4/18/2024, 7:22:16 PM)

After market: 327.52 0 (0%)

327.52

+0.02 (+0.01%)

SWAV News

News Image21 hours ago - InvestorPlaceWant to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.

Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.

News Image2 days ago - ChartmillNASDAQ:SWAV: a strong growth stock preparing for the next leg up?.

Is SHOCKWAVE MEDICAL INC (NASDAQ:SWAV) on the Verge of a Major Breakout as a Strong Growth Stock?

News Image3 days ago - Brodsky & Smith LLCBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
News Image4 days ago - Brodsky & Smith LLCBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)
News Image8 days ago - InvestorPlaceWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.

News Image8 days ago - InvestorPlaceAll-Time High Flyers: 7 Stocks to Buy as the Market Peaks

These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak.

News Image9 days ago - InvestorPlaceWall Street Favorites: 3 Dividend Stocks With Strong Buy Ratings for April 2024

These three dividend kings are among the most reliable dividend stocks, and each has at least one strong buy rating.

News Image9 days ago - The Motley FoolDoes Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?

The company is hoping to expand, but is there enough here to attract growth investors?

News Image9 days ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, INRD

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image10 days ago - The Motley Fool3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

News Image10 days ago - Kahn Swick & Foti, LLCSHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
News Image11 days ago - Shockwave Medical, Inc.Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina

SWAV Links
Follow us for more